SPONSORED CONTENT
TIP: Accurately tracking and loading drug prices into the ESP system can be the difference maker when it comes to maintaining compliance and
SPONSORED CONTENT
TIP: Accurately tracking and loading drug prices into the ESP system can be the difference maker when it comes to maintaining compliance and
SPONSORED CONTENT
Will you be attending the 340B Winter Coalition Conference in San Diego? Start your week with the latest developments in the 340B program. This year, Verity Solutions will be hosting a panel discussion on Monday morning with some of the most respected long-term experts on the 340B program, including Ted Slafsky, Publisher & CEO of 340B Report and Bill von Oehsen, Principal of Powers Law. Join us for an up-to-the-minute report on hot button topics related to the legislative, legal and regulatory aspects of the 340B program. Among the matters to be covered:
In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program and provide the best care to those they serve.
About our guest, Ted Slafsky:
Publisher and Chief Executive Officer of 340B Report, Ted is a long-time healthcare thought leader and journalist. He is the Founder & Principal of Wexford Solutions LLC, has three decades of experience in 340B and journalism.
SPONSORED CONTENT
This past November, the 340B program celebrated its 30th anniversary—a huge milestone and a reason to rejoice and reflect. We are dismayed, however, that certain drug manufacturers are trying to revise the 340B program’s past and reimagine its future. More than 20 drug manufacturers have unilaterally and unlawfully placed restrictions on contract pharmacy arrangements which have diminished the value of the 340B programs for communities in need. [1] However, it is vital to note that, in the last thirty years, the need for outpatient drugs to treat patients has grown exponentially, as has the price of drugs, making the 340B program more crucial than ever for safety net providers and their patients.
Most of us know that Congress passed the 340B statute in 1992 to enable covered entities “to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” But did you know that, when Congress was drafting the
…SPONSORED CONTENT
The rise in digital technologies in the healthcare sector during the COVID-19 pandemic has resulted in some interesting trends in medical communication as we move closer to a post-pandemic world.
During the pandemic, patients became more engaged with medical communication than ever. They went from attending doctor’s visits in-person to making telehealth appointments. In addition, due to forced shutdowns, even the less tech-savvy patients learned how to navigate the internet in new ways to find information and stay connected with their healthcare providers (HCPs).
In addition to using digital mediums to communicate with their care teams, patients turned to the internet to learn more about the virus. They became comfortable performing research rather than waiting to hear what their doctor had to say, and they gained trust in the medical professionals who were providing them with frequent updates on the state of the virus.
So, the last three years have had a significant impact on the ways medical communication is
…SPONSORED CONTENT
Recent surveys confirm what those of you reading this know painfully well: Hospital and clinic pharmacies are struggling from the restrictions drug manufacturers are placing on 340B pricing at contract pharmacy sites. As the 340B world awaits another batch of court rulings and hopes for the best, the exclusions are harming patients’ ability to access vital medications and safety net services and delivering a serious blow to hospital and other 340B covered entity finances.
Healthcare providers can’t wait around and count on help from the courts, Congress, or the Biden administration. They need options, now, to restore their margins and ensure they can continue to serve their most vulnerable patients.
At The Craneware Group, we’ve been writing about ways covered entities can regain ground lost to the drug manufacturers and their unlawful actions. We’ve also been evaluating the utilization of biosimilars. By closely examining the 19 manufacturers restricting 340B pricing
…SPONSORED CONTENT
The healthcare industry is grappling with a severe staffing shortage, and pharmacies are no exception. More than three-quarters of community pharmacists are struggling to fill open positions, and nearly 90% say finding pharmacy technicians is their top staffing problem, according to a recent survey by the National Community Pharmacists Association.
As a senior talent advisor for pharmacy operations at Maxor, these statistics don’t surprise me. In the more than 30 years I’ve spent recruiting pharmacists, pharmacy technicians, and front-office staff for community and 340B pharmacies—including during the severe pharmacist shortage in the 1990s—this is the most challenging labor market I’ve ever experienced.
At Maxor, my team and I are responsible for staffing numerous pharmacies across the country for both rural and urban covered entities, including FQHCs, community health centers, HIV specialty and Ryan White clinics, and outpatient hospital pharmacies. Despite the challenging labor market, we’ve continued to successfully
…SPONSORED CONTENT
The monkeypox (renamed mpox by the World Health Organization) outbreak took the world by storm in early May of 2022 on the heels of the COVID-19 pandemic. The AIDS Healthcare Foundation (AHF) was among the first public health organizations to sound the alarm on mpox, notably found at a higher rate among men who have sex with men (MSM), bringing attention to the outbreak in June of 2022. After the World Health Organization reported viral DNA found in the semen of a handful of mpox patients in Italy and Germany, AHF urged the Centers for Disease Control and Prevention to promote condom use.
To further spread awareness for mpox and raise caution to at-risk communities, AHF held multiple press teleconferences. These teleconferences informed media outlets of the rapidly increasing mpox cases in Los Angeles County and the extremely limited vaccine doses available nationwide. During the conferences, AHF called on the Los Angeles
…SPONSORED CONTENT
Increasingly, participants in Accountable Care Organizations (ACOs) are discovering and benefiting from the 340B drug discount program. Unlike the historic fee-for-service healthcare models, ACOs are rewarded for outcomes that are better aligned with value-based population health, including improved patient care outcomes, an enhanced patient experience, and more efficient, streamlined provider time where physicians spend more time with patients who are most acute, all while lowering overall costs.
By participating in the 340B program, eligible hospitals and clinics are better positioned to put patient care first. When combined with ACO participation, new drug savings and revenue are generated to further efforts to enhance patient care while lowering costs at a time when the field of healthcare is experiencing unprecedented stressors – both professionally and financially.
Safety-net providers have demonstrated success in accountable care through a collaborative ACO model. In a collaborative, independent providers work together to improve operational efficiencies and quality of care
…SPONSORED CONTENT
We are pleased to again bring you Visante’s Top 10 issues in pharmacy for 2023. For 2022, our Top 10 items (Pharmacy Org Structure, 340B Program, Vertical Integration & Marketplace Restrictions, Drug Prices & Supply Chain, Infusion Services, Drug Shortages, Pandemic, Economy, Election, Social Justice) all turned out to be very relevant and many of these items again made the list for 2023.
To say that 2022 was turbulent would be a significant understatement! With the pandemic, economy, election and social justice issues driving national concerns, including pharmacy, coupled with the more pharmacy-specific elements, it was an extremely challenging year for pharmacy and healthcare in general. However, despite the magnitude of the challenges, we observed pharmacy programs all over the country stepping up and meeting these challenges head-on. Pharmacy programs demonstrated innovation, creativity, commitment to purpose, and a tremendous work ethic in supporting their patients and their organizations and should be justifiably proud of their
…*Sign up for news summaries and alerts from 340B Report